Literature DB >> 8763262

Abnormal expression of the human CD44 gene in early colorectal malignancy with special reference to variant exon 9 (9v).

K Kawahara1, T Yoshino, N Kawasaki, K Miyake, T Akagi.   

Abstract

AIMS: To examine the expression of CD44 variant exon 9 in early colorectal malignancies.
METHODS: Formalin fixed, paraffin wax embedded tissue sections from 30 cases of tubular adenoma and 35 cases of adenoma with focal carcinoma of the colon were examined immunohistochemically using a monoclonal antibody (MAb 11.24) directed against CD44-9v.
RESULTS: In the normal colorectal mucosa immunoreactivity was confined to the basal part of the crypts and was expressed in less than 10% of crypt cells. CD44-9v was expressed in the superficial part of tubular adenoma with mild atypia in 67% of the cases and in 19% of the tumour cells. The immunoreactivity was observed along the basement membrane in mild atypia, as in the non-neoplastic crypts. In the course of progression to severe atypia the spatial polarity of immunoreactivity was lost, and the extent of CD44-9v expression increased in intensity and in the percentage of positive cases and positive cells. In the carcinomatous lesions of adenoma with focal carcinoma, 94% of the cases and 44% of the tumour cells were positive for CD44-9v protein.
CONCLUSION: CD44-9v may be overexpressed at the early stage of colorectal tumorigenesis and this increase continues throughout the course of the disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8763262      PMCID: PMC500538          DOI: 10.1136/jcp.49.6.478

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  19 in total

Review 1.  A genetic model for colorectal tumorigenesis.

Authors:  E R Fearon; B Vogelstein
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

2.  The evolution of cancer of the colon and rectum.

Authors:  T Muto; H J Bussey; B C Morson
Journal:  Cancer       Date:  1975-12       Impact factor: 6.860

3.  A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells.

Authors:  U Günthert; M Hofmann; W Rudy; S Reber; M Zöller; I Haussmann; S Matzku; A Wenzel; H Ponta; P Herrlich
Journal:  Cell       Date:  1991-04-05       Impact factor: 41.582

4.  Significance of CD44 gene products for cancer diagnosis and disease evaluation.

Authors:  Y Matsumura; D Tarin
Journal:  Lancet       Date:  1992-10-31       Impact factor: 79.321

5.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons.

Authors:  G R Screaton; M V Bell; D G Jackson; F B Cornelis; U Gerth; J I Bell
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

Review 6.  CD44--a molecule involved in leukocyte adherence and T-cell activation.

Authors:  B F Haynes; M J Telen; L P Hale; S M Denning
Journal:  Immunol Today       Date:  1989-12

7.  Small nonpolypoid carcinomas of the large intestine.

Authors:  B E Crawford; F W Stromeyer
Journal:  Cancer       Date:  1983-05-01       Impact factor: 6.860

8.  CD44 variant isoforms are preferentially expressed in basal epithelial of non-malignant human fetal and adult tissues.

Authors:  H J Terpe; H Stark; P Prehm; U Günthert
Journal:  Histochemistry       Date:  1994-02

Review 9.  CD44: the hyaluronan receptor.

Authors:  C Underhill
Journal:  J Cell Sci       Date:  1992-10       Impact factor: 5.285

10.  A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps.

Authors:  K H Heider; M Hofmann; E Hors; F van den Berg; H Ponta; P Herrlich; S T Pals
Journal:  J Cell Biol       Date:  1993-01       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.